Начало › Рак на гърдата › Колорадо › Denver
Клинични проучвания за Рак на гърдата в Denver, CO
28 проучвания за Рак на гърдата търсят участници в обекти в и около Denver (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Набиране на участнициФаза 1/2
- Rocky Mountain Cancer Center, Denver
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Набиране на участнициФаза 3
- Rocky Mountain Cancer Centers, Denver
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Набиране на участнициНаблюдателно проучванеЗдравите доброволци са добре дошли
- AdventHealth Porter, Denver
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Набиране на участнициФаза 2
- Rocky Mountain Cancer Centers, Denver
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Набиране на участнициФаза 1
- Sarah Cannon Research Institute (Scri) At Health One, Denver
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Набиране на участнициФаза 3
- Intermountain Health Cancer Center Saint Joseph ( Site 0062), Denver
- Rocky Mountain Cancer Centers (RMCC) ( Site 8006), Denver
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Набиране на участнициФаза 3
- UCHealth Cherry Creek Medical Center ( Site 0094), Denver
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Набиране на участнициФаза 3
- UCHealth Cherry Creek Medical Center, Denver
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Набиране на участнициФаза 3
- Research Site, Denver
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Набиране на участнициФаза 2
- Saint Joseph Hospital - Cancer Centers of Colorado, Denver
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Набиране на участнициФаза 3
- Clinical Trial Site, Denver
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Набиране на участнициФаза 3
- St. Joseph Hospital-Cancer Centers of Colorado, Denver
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Набиране на участнициФаза 1/2
- Skin Cancer Institute, Englewood · на 6 мили
The Vanguard Study: Testing a New Way to Screen for Cancer
Набиране на участнициЗдравите доброволци са добре дошли
- Kaiser Permanente-Franklin, Denver
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Набиране на участнициФаза 3
- UCHealth - Cherry Creek, Denver
- Saint Joseph Hospital - Cancer Centers of Colorado, Denver
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Набиране на участнициФаза 1
- Sarah Cannon Research Institute at HealthONE, Denver
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Набиране на участнициФаза 1
- Sarah Cannon Research Institute - Denver DDU, Denver
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Набиране на участнициФаза 1
- Sarah Cannon Research Institute (SCRI) at HealthONE-Denver, Denver
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Набиране на участнициФаза 2/3
- Rocky Mountain Cancer Centers, Denver
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Набиране на участнициФаза 3
- Rocky Mountain Cancer Centers, Denver
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Набиране на участнициФаза 3
- Rocky Mountain Cancer Centers LLP, Denver
- Rocky Mountain Cancer Centers LLP, Englewood · на 6 мили
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Набиране на участнициФаза 1/2
- Sarah Cannon Research Institute, Denver
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Набиране на участнициФаза 3
- UCHealth - Cherry Creek, Denver
- Rose Medical Center, Denver
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Набиране на участнициНаблюдателно проучване
- Kaiser Permanente-Franklin, Denver
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Centers-Midtown, Denver
- и още 1
The Immune System's Response to Young Women's Breast Cancer
Набиране на участнициНаблюдателно проучване
- Denver Health Hospital Authority, Denver
- UCHealth Cherry Creek Medcial Center, Denver
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Набиране на участнициНаблюдателно проучване
- Massive Bio SYNERGY-AI site, Denver
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Набиране на участнициФаза 1
- HealthONE, Denver
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Набиране на участнициНаблюдателно проучване
- Comprehensive Breast Care of Denver, Denver
Проучвания за Рак на гърдата в други градове
- New York City, NY134 проучвания
- Houston, TX126 проучвания
- Boston, MA111 проучвания
- Nashville, TN80 проучвания
- Los Angeles, CA72 проучвания
- Edison, NJ68 проучвания
- St. Louis, MO64 проучвания
- Durham, NC63 проучвания
- Queens, NY63 проучвания
- Chicago, IL58 проучвания
- Philadelphia, PA56 проучвания
- Dallas, TX55 проучвания
Други проучвания в Denver
- Метастатичен рак29 проучвания
- Множествен миелом27 проучвания
- Рак на белия дроб с недребноклетъчен тип27 проучвания
- Колоректален рак23 проучвания
- Рак на простатата19 проучвания
- Меланом19 проучвания
- Рак (всички видове)18 проучвания
- Рак на яйчниците16 проучвания
- Рак на белия дроб16 проучвания
- Ендометриален рак15 проучвания
- Нон-Ходжкинов лимфом14 проучвания
- Рак на панкреаса13 проучвания
От ClinicalTrials.gov, данни към 5.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.